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Abstract
Background
Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated
with anthracycline and taxane. We argued that E could also benefit patients eligible for
neoadjuvant chemotherapy.
Methods
Patients with primary triple negative breast cancer�2 cm received doxorubicin 60 mg/m2
and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary end-
point was pathological complete response (pCR) rate; secondary and explorative endpoints
included clinical/metabolic response rates and safety, and biomarker analysis, respectively.
Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13
patients had achieved pCR in the first stage of the study.
Results
In stage I of the study 13 women were enrolled, median age 43 years, tumor size 2–5 cm in
9/13 (69%), positive nodal status in 8/13 (61%). Main grade 3 adverse event was neutrope-
nia (related to AT and E in 4 and 2 cases, respectively). AT followed by E induced clinical
complete + partial responses in 11/13 patients (85%), pCR in 3/13 (23%). Median measure-
ments of maximum standardized uptake value (SUVmax) resulted 13, 3, and 1.9 at base-
line, after AT and E, respectively. Complete metabolic response (CMR) occurred after AT
and after E in 2 and 3 cases, respectively. Notably, 2 of the 5 (40%) patients with CMR
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achieved pCR at surgery. Immunostaining of paired pre-/post-treatment tumor specimens
showed a reduction of β-catenin, CyclinD1, Zeb-1, and c-myc expression, in the absence of
N-cadherin modulation. The study was interrupted at stage I due to the lack of the required
patients with pCR.
Conclusions
Despite the early study closure, preoperative E following AT showed clinical and biological
activity in triple negative breast cancer patients. Furthermore, the modulation of β-catenin
pathway core proteins, supposedly outside the domain of epithelial–mesenchymal transi-
tion, claims for further investigation.
Trial registration
EU Clinical Trial Register, EudraCT number 2012-004956-12.
Introduction
Triple negative breast cancer (TNBC), which accounts for 10–20% of all breast cancer (BC)
cases, is defined by the lack of expression of hormone receptors, estrogen receptor (ER) and
progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) [1], and
is associated with poor prognosis [2]. Due to the absence of any actionable target, treatment of
TNBC relies on chemotherapy since the very early stage of disease. Over the past decades, a
large number of adjuvant randomized clinical trials have been conducted to define the optimal
chemotherapy, dosing and scheduling, and finally establish the efficacy of anthracycline and
taxane-based regimens [3]. Evidence from these trials supports the concept of a threshold
effect, thereby indicating that under-dosing of these active agents is associated with a poorer
clinical outcome. However, escalation of dosage in dose-dense and dose-intense regimens is
still under debate as in general it comes at the expense of increased toxicity [4]. For this reason,
research into alternatives to improve the prognosis of TNBC patients has intensified, resulting
in the development of new active compounds with a favorable safety profile even after treat-
ment or in combination with anthracycline and taxane [5].
Eribulin mesylate (E, E7389; Halaven) is a non-taxane microtubule dynamics inhibitor able
to induce cell cycle arrest in the G2-M phase by forming abnormal mitotic spindles that cannot
pass the metaphase/anaphase checkpoint with subsequent apoptosis [6–8].
A pooled analysis of two phase III clinical trials of E in heavily pre-treated metastatic BC
patients reported a significant 4.7 month increase in overall survival (OS) compared with con-
trols in the TNBC population [9]. Similarly, the OS in favor of E over capecitabine in Study
301, which involved women with�2 prior lines of treatment for advanced disease, was most
pronounced in the TNBC population (14.4 vs 9.4 months; p = 0.01) [10]. These observations
have sparked considerable interest in the use of E in this BC subtype even beyond the meta-
static setting [11–12]. Preoperative systemic (neoadjuvant) treatment of BC yields clinical out-
come results similar to those of adjuvant systemic therapy, and improves breast conservation
rates because of tumor response to therapy [13]. The preoperative setting also allows monitor-
ing of response to therapy in previously untreated patients. In TNBC, pathological complete
response (pCR) at the time of surgery has been shown to correlate with improved disease
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outcomes in randomized clinical trials suggesting that it may serve as a favorable prognostic
factor [14].
Based on the antitumor activity of E in anthracycline and taxane pretreated TNBC patients,
and considering the unique opportunity of the neoadjuvant setting as a platform to develop a
novel antitumor strategy, we designed the multicenter, prospective, non-randomized, open-
label, single-arm, two stage, phase II “Halaven as preOPerative therapy in brEast cancer
(HOPE)” trial to evaluate the antitumor activity of E following anthracycline and taxane, and
correlative studies attempting to identify predictors of response in localized TNBC patients.
Materials and methods
Study patient population
Patients with confirmed clinical stage I-III TNBC and a minimum primary tumor size of 2 cm
in largest diameter, assessed by clinical examination and breast imaging (ie mammography ±
breast ultrasound ± breast magnetic resonance) were included in the study. Patients with mul-
tifocal tumors were eligible if the largest lesion was� 2 cm. Estrogen receptor (ER), progester-
one receptor (PgR), and HER2 status were tested locally by immunohistochemistry (IHC).
Patients were considered eligible if ER and PgR status was < 1% and HER2 status was 0 or 1+
by IHC; in case of a 2+ result, an in-situ hybridization (FISH/CISH) was performed, and the
patient was included when < 4 HER2 copies per nucleus or FISH ratio < 1.8 were found. An
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, adequate
bone marrow, renal and hepatic functions, were required. Bilateral or inflammatory breast
cancer patients were excluded. Patient recruitment was done consecutively until the desired
sample size was reached, and relied on physician referrals in participating sites, including
three community hospitals, ie the ASST Monza, Cremona, and Fatebenefratelli-Sacco, and the
comprehensive cancer center Fondazione IRCCS Istituto Nazionale dei Tumori—Milano
(INT), which coordinated the study.
Ethical statement
This study was approved by local institutional ethical committees (Comitato Etico ASST
Monza, Comitato Etico Val Padana, Cremona, Comitato Etico Milano Area B, Comitato Etico
della Fondazione IRCCS Istituto Nazionale dei Tumori—Milano), and was conducted in
accordance with the principles of the 18th World Medical Assembly (Helsinki, 1964). All appli-
cable amendments were laid down by the World Medical Assemblies and the ICH guidelines
for Good Clinical Practice (GCP). Written informed consent was obtained from each partici-
pant in the trial. EUDRACT number was 2012-004956-12.
Study procedures
In each participating site, patients received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2
(AT) on day 1 of a 21-day cycle for a total of 4 cycles [15], followed by E 1.4 mg/m2 as a 2–5
min IV bolus injection on days 1 and 8 of a 21 day cycle, for 4 cycles. Complete blood count
and biochemistry were required before the initiation of chemotherapy and on day 1 of each
cycle with AT, and on days 1 and 8 of each cycle with E. After completion of the four cycles of
E, patients underwent surgical excision, carried out 3 to 5 weeks after completion of study
treatment. The type of breast surgery and the management of the axilla followed local standard
practice. Surgical specimens were collected for pathologic examination and biomarker analy-
sis. The pathological results of the surgical specimens were collected for the purpose of the pri-
mary endpoint analysis. After surgery, additional adjuvant chemotherapy ± radiotherapy were
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permitted. The type of adjuvant treatment was as per investigator´s choice and local standard
of care. Patients participated in this study until completion of treatment, unacceptable toxicity,
disease progression, or consent withdrawal.
At baseline, tumor assessment included mammography ± breast ultrasound ± breast mag-
netic resonance imaging according to local expertise (within 21 days of initiating study treat-
ment). Tumor size was measured in centimeters according to RECIST 1.1.
18F-FDG PET/CT scan for initial tumor staging, clinical evaluation and standard laboratory
tests were required at baseline. Chest 18F-FDG PET/CT scan was repeated after 4 cycles of AT,
and after 2 cycles of E for the protocol specific purpose of metabolic response evaluation. All
18F-FDG PET/CT images had to be taken using the same scanner (hybrid PET/CT system 64
TOF Gemini; Philips Medical Systems) and identical acquisition parameters at INT. Two
nuclear medicine reviewers were dedicated to assess both the quality of the scans and the imag-
ing analysis. EORTC criteria were applied to assess tumor response [16], and complete meta-
bolic response was complete resolution of 18F-FDG uptake within all lesions, making them
indistinguishable from surrounding tissue. Clinical tumor assessment by physical examination
was required before the initiation of chemotherapy and on day 1 of each cycle. Tumor radio-
logical re-assessment was done after 3 weeks from the last administration of AT (± 5 days). As
per protocol, the end of study visit was scheduled on the day of surgery, though patients were
convened for a follow up visit 30 days (with a 7 days window) after definitive surgery. The
expected study duration was 18 months for patient accrual, and additional 12 months for
safety follow up from the start of study treatment. Data were obtained locally and the central
study database was audited by INT.
Study objectives
The primary objective of this trial was to evaluate the antitumor activity of E combined with
an anthracycline/taxane-based regimen given as primary systemic therapy and assessed as
pathological complete response rate, defined as the absence of invasive cancer in both the
breast and axillary lymph nodes.
Secondary objectives included clinical objective response rate (ORR) as defined by RECIST
criteria version 1.1; the overall safety profile and tolerability of E; the association between
18F-FDG PET/CT and tumor response in terms of pCR; the predictive value of early 18F-FDG
PET/CT imaging to evaluate the response to AT, to E and their relationship; as an explorative
endpoint, the effect of E following AT on the expression levels of epithelial to mesenchymal
transition (EMT) biomarkers.
Statistical analysis
A Simons’s optimal two-stage design was applied. The sample size was estimated based on
expected values of pCR [17] of 40% under the alternative hypothesis and 20% under the null
hypothesis. With a type I error of 0.05 and a statistical power of 80%, 13 patients were planned
in the first stage. In case of 3 pCRs or fewer in this first stage, the accrual would be stopped. If 4
or more pCRs were observed, accrual would continue to include 43 patients overall. At the end
of the trial, if more than 13 pCRs were observed among the 43 patients treated with E following
AT the null hypothesis would have been rejected. Estimation and testing of the response rate
were based on the exact binomial distribution. Descriptive statistics were used to summarize
patient characteristics, diagnosis, treatment administration and compliance, activity end-
points, safety parameters and possibly even cancer biomarkers.
The analyses were conducted using the Statistical Analysis System (SAS, SAS Institute Inc.,
Cary, NC, USA) and R software.
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Immunohistochemical analysis
Tumor biopsies and surgical tumor tissue samples were fixed in 10% buffered formalin and
paraffin embedded. Four-micrometers-thick tissue sections were deparaffinized and rehy-
drated. The antigen unmasking was performed using Novocastra Epitope Retrieval Solutions
pH6; pH 8 and pH 9 in a PT Link pre-treatment module (Dako, Denmark) at 98˚C for 30 min-
utes. The sections were brought to room temperature and washed in PBS. After neutralization
of the endogenous peroxidase with 3% H2O2 and Fc blocking by a specific protein block
(Novocastra UK) the samples were incubated overnight with the primary antibodies Rabbit
Monoclonal anti-human β-catenin, dilution 1:100 pH8 [Clone 6B3; Cell Signaling]; Rabbit
Polyclonal anti-human N-cadherin, dilution 1:500 pH9 [AbCam Code ab18203]; Rabbit
Monoclonal anti-human c-myc, dilution 1:500 pH6 [Clone Y69; AbCam Code ab32072];
Mouse Monoclonal anti-human Zeb-1, dilution 1:150 pH6 [Clone 3G6; AbCam Code
ab180905]; Mouse Monoclonal anti-human Cyclin D1, dilution 1:25 pH9 [Clone P2D11F11;
Leica Novocastra], at 4 C˚. Staining was revealed by polymer detection kit (Novocastra) and
AEC (3-amino-9-ethylcarbazole) or DAB [3,3- diaminobenzidine tetrahydrochloride] sub-
strate-chromogen. The slides were counterstained with Harris hematoxylin (Novocastra). All
the sections were analysed under an AXIO Scope A1 optical microscope (ZEISS) and micro-
photographs were collected through an Axiocam 503 Color digital camera (Zeiss) using the
Zen2 software.
The immunostaining for Cyclin D1, c-myc, and Zeb-1 was scored according to the percent-
age of positive cells. For the determination of the EMT score, Zeb-1 expression was categorized
as follows: 0 negative, 1 around 5%, 2 10–15%, 3 20–25%, 4 30–35%, 5 40–45%, 6>50%. β-
catenin and N-cadherin were scored according to the intensity of the membrane staining as
follows: 0 negative, 1 dim expression in less than 50% of cells or intense expression in less than
10% of cells, 2 dim expression in more than 50% of cells or strong expression in >10%<50%
of cells, 3 strong expression in more than 50% of cells. The EMT score was calculated as the
result of the formula (N-cadherin + Zeb-1 score) ─ β-catenin score. Evaluation of each param-
eter and EMT scoring were done independently by two pathologists (CT and AG) in a blinded
fashion (i.e. without any knowledge of the patient ID, clinical outcome, and order of pre- and
post-treatment tumor samples).
Results
Between August 23, 2013 and March 9, 2015, a total of 13 patients met eligibility criteria and
were enrolled in the study. The study flowchart is reported in Fig 1. Patient clinical and patho-
logical features are reported in Table 1. The median age was 43 (range 35–75) years. At diagno-
sis tumor size was 2–5 cm (cT2) in 9/13 (69%), and> 5 cm (cT3) in 4/13 (30%) patients, with
a median value of 4.0 (2.2–7.5) cm; clinical nodal status was positive (cN1-3) in 8/13 (61%)
cases. No case of stage I TNBC was enrolled.
Histologic grade 3 was reported in 8/9 (88.8%) evaluable patients. Among 11 evaluable
patients, the median Ki67 value was 55% with a range of 25% to 90%. Four and 7 patients had
primary tumors with an intermediate (25%–50%) and high (>50%) Ki67 staining, respectively.
No case of low Ki67 primary tumor was reported.
Toxicity data were recorded for all 13 patients.
Table 2 lists the most common adverse events before and after treatment with E. Treatment
was in general well tolerated. In particular, the most frequent adverse events were represented
by G3 and G4 neutropenia, which were related to AT in 4, and to E in 2 cases, respectively.
Data on objective response rates are summarized in Table 3. Major shrinkage of the pri-
mary tumor was measured in 84% of patients (complete response 8%; partial response 76%)
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after primary AT followed by E. An analysis of the degree of response after AT and after E was
feasible in 11 cases. Overall, 6/11 (54%) patients achieved a partial response after AT; 3/5
(60%) patients who did not respond to AT reported a partial response after E; one patient
maintained a stable disease, and 1 progressed.
Fig 1. HOPE study flowchart. Doxorubicin/Paclitaxel (AT); Eribulin (E). One patient did not complete the pre
planned treatment with AT x 4 cycles followed by E x 4 cycles, as she underwent surgery soon after the second cycle of
E, due to progressive disease.
https://doi.org/10.1371/journal.pone.0220644.g001
Table 1. Patients and tumor characteristics.
N.
AGE
<50 years 9
�50 years 4
CLINICAL TUMOR SIZE
2–5 cm 9
>5 cm 4
CLINICAL NODAL STATUS
N0 5
N1-3 8
TUMOR GRADE
G2 1
G3 8
Missing 4
Ki67
<50% 4
�50% 8
Missing 1
https://doi.org/10.1371/journal.pone.0220644.t001
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After primary AT followed by E, 13 patients underwent surgery. Pathological findings were
available for all patients. Three out of 13 (23%) patients achieved a less than 1 cm residual dis-
ease. Complete absence of invasive cancer in breast and axillary nodes, ie pCR as per protocol
definition, was reported in 3/13 (23%) patients. With a median follow up of 49 months (range
47–54), the event free survival (EFS), defined as the time from study treatment initiation to
first EFS event (breast cancer relapse, second primary malignancy or death without recur-
rence) was 61%. None of the patients achieving pCR relapsed.
Correlative studies
Chest 18F-FDG PET/CT scans were available in 12, 13 and 12 patients at baseline, after AT and
after 2 cycles of E, respectively. Measurements of the median maximum Standardized Uptake
Value (SUV max) were 13, 3, and 1.9 at baseline, after AT and after E, respectively. As com-
pared to basal values, median SUVmax measurements of primary tumor resulted 26.2% (95%
CI 13.2–39.2) and 22.6% (95%CI 0.33–44.9) after AT and E, respectively. Box plots of the
changes in SUVmax measurements are shown in Fig 2. Five patients attained a CMR, 2 after
AT and additional 3 after E. Two out of these 5 patients achieved pCR at the time of surgery.
Table 2. Main toxicities.
TOXICITY ANTHRACYCLINE + TAXANE ERIBULIN
All grades G3 G4 All grades G3 G4
HAEMATOLOGICAL
Anaemia 6 (46%) 0 (0%) 0 (0%) 7 (54%) 0 (0%) 0 (0%)
Neutropenia 5 (38%) 1 (8%) 3 (23%) 7 (54%) 2 (15%) 0 (0%)
Leucopenia 1 (8%) 1 (8%) 0 (0%) 2 (15%) 0 (0%) 0 (0%)
NON-HAEMATOLOGICAL
Peripheral neuropathy 6 (46%) 0 (0%) 0 (0%) 7 (54%) 0 (0%) 0 (0%)
ALT 6 (46%) 0 (0%) 0 (0%) 6 (46%) 0 (0%) 0 (0%)
AST 4 (31%) 0 (0%) 0 (0%) 4 (31%) 0 (0%) 0 (0%)
Nausea 4 (31%) 0 (0%) 0 (0%) 4 (31%) 0 (0%) 0 (0%)
Myalgia 4 (31%) 1 (8%) 0 (0%) 4 (31%) 0 (0%) 0 (0%)
Astenia 3 (23%) 0 (0%) 0 (0%) 3 (23%) 0 (0%) 0 (0%)
Vomiting 2 (15%) 0 (0%) 0 (0%) 7 (54%) 1 (8%) 0 (0%)
Mucosal inflammation 2 (15%) 0 (0%) 0 (0%) 3 (23%) 0 (0%) 0 (0%)
Conjunctivitis 1 (8%) 0 (0%) 0 (0%) 6 (46%) 0 (0%) 0 (0%)
https://doi.org/10.1371/journal.pone.0220644.t002
Table 3. Clinical and pathological treatment response to E following AT.
CLINICAL RESPONSE N (%)
PARTIAL RESPONSE 10 (76%)
COMPLETE RESPONSE 1 (8%)
PROGRESSIVE DISEASE 1(8%)
STABLE DISEASE 1(8%)
PATHOLOGICAL FINDINGS
ypT0N0 3 (23%)
ypT1bN0 3 (23%)
ypT1bN1 1 (8%)
ypT1cN0 3 (23%)
ypT2N0 2 (15%)
ypT2N1 1 (8%)
https://doi.org/10.1371/journal.pone.0220644.t003
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Fig 3 shows EMT biomarker levels in all available basal (8 cases) and surgical (5 cases) pri-
mary tumor samples. Immunoreactivity for β-catenin and N-cadherin was detected in all pri-
mary tumor biopsies at baseline, and resulted moderate in 66% and 50% of cases, respectively.
Besides, median pre-treatment rate of positive tumor cells for c-myc, Cyclin D1, and Zeb-1
were 30% (range 10–60%), 50% (15–60%), and 12% (5–25%), respectively. In five cases with
paired pre- and post-treatment primary tumor tissue, we observed that β-catenin was unde-
tectable in 3/5 (60%) cases and halved in one additional case after AT followed by E. Notably,
this effect was not paralleled by N-cadherin, whose expression fell to zero just in one case. c-
myc was undetectable in 60% of cases, Cyclin D1 dropped to levels�5% in 80% of cases,
whereas the rate of Zeb-1 doubled in 60% of surgical samples (Fig 3).
Hence, modulation of the Wnt/β-catenin pathway in tumor samples of patients treated
with E following AT could involve c-myc signalling, independently of EMT feature changes
(immune-staining index panel, showed in Fig 4.
Discussion
Systemic chemotherapy represents the mainstay of treatment for TNBC and maximizing the
rate of pCR is widely considered the most important outcome for preoperative chemotherapy
against TNBC. Nevertheless, the optimal neoadjuvant regimen in TNBC patients has not been
clearly defined. Current controversies in the field include the role of platinum salts, the optimi-
zation of taxane formulations, and the use of biologic agents. Conflicting results of major stud-
ies with platinum-based compounds have highlighted the need to balance potential benefits
against increased toxicity [18–21]. Data concerning optimal taxane schedules support the use
of nab-paclitaxel instead of paclitaxel in selected cases [22–24]. PARP inhibitors deserve addi-
tional studies as preliminary data in combination with chemotherapy showed a marginal pCR
advantage [25].
The rationale for combination chemotherapy is to use agents with non-overlapping mecha-
nisms of action and established safety profiles. Eribulin mesylate (E) is a new generation
Fig 2. Box- plot of SUV max in TNBC patients at baseline, after treatment with AT, and after E. The boxes
represent the 25–75% range with bisecting lines showing the median values, and the horizontal lines represent the 10–
90% range.
https://doi.org/10.1371/journal.pone.0220644.g002
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chemotherapy agent with a specific mechanism of action and antitumor activity against a wide
range of tumor types, including drug-resistant BC. Of note, anthracycline- and taxane-resis-
tant metastatic BC patients are known to be sensitive to E as a single agent [26]. Importantly,
significant anticancer activity is seen in ER, PgR and HER2 negative metastatic BC cases [10].
So far few studies evaluating E in localized BC either in combination with carboplatin [27],
and trastuzumab [28], or as monotherapy [29] after anthracycline-based chemotherapy have
been reported. Overall, results showed that E has a favorable peripheral neuropathy toxicity
profile, without any clearly improved activity over historical results with standard treatment
with paclitaxel [28]. Our study is the first in literature with neoadjuvant E following anthracy-
cline and taxane in patients with localized TNBC. We aimed to address the antitumor activity
of an intense neoadjuvant regimen with doxorubicin and paclitaxel followed by E, and to
explore the potential of E anthracycline- and taxane non responders in localized TNBC.
Unfortunately, the pCR rate failed to meet our criteria for continuing this trial beyond stage I.
Our interim analysis revealed that only three of 13 patients had pCR -below the pre-established
futility boundary-so the trial was interrupted.
Several explanations for the lack of E activity in terms of pCR in this trial can be given. We
can hypothesize greater activity in patients with earlier-stage disease. Most of the patients
enrolled had large primary tumor size and positive nodal status while the study hypothesis was
built on prior neoadjuvant studies which also enrolled stage I-IIA breast cancer patients[13–
Fig 3. Epithelial to mesenchymal transition biomarker levels in primary tumor samples. Spaghetti plot of the
changes of primary tumor immunostaining of individual patients at baseline and after study treatment with
neoadjuvant AT followed by E. Immunostaining for the indicated biomarkers was performed on 13 primary tumor
specimes, specifically 8 pre-treatment, 5 post-treatment, and 5 paired-biopsies (missing information at surgery in 3
cases: 1 pCR, 2 insufficient amount of residual tumor). Five patients are not represented due to lack of evaluable
primary tumor tissue at both baseline and at surgery. Epithelial–mesenchymal transition (EMT); EMT scores,
estimated as reported in the Methods section.
https://doi.org/10.1371/journal.pone.0220644.g003
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Fig 4. Immune-staining index panel. Specific reaction with β-catenin, N-cadherin, Cylin D1, c-myc and Zeb-1
monoclonal antibodies in primary TNBC before and after neoadjuvant therapy with AT followed by E. Intense
immunostaining was evident in pre-treatment primary tumor biopsy, whereas it appeared reduced in surgical
specimen after study treatment, with the unique exception of N-cadherin, whose levels remained stable. Scale bar,
reported at the right bottom of each picture.
https://doi.org/10.1371/journal.pone.0220644.g004
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14]. It should be noted that E induced response in 60% of unresponsive cases to doxorubicin
and paclitaxel (AT). Albeit the sample size was limited, this “rescue” rate seems to be superior
to that reported by Gianni et al. with the use of the CMF schema after AT [30]. Furthermore,
we showed that E can increase the proportion of patients who achieved a complete metabolic
response in TNBC patients who were predicted to be unlikely to respond to AT by 18F-FDG
PET/CT imaging. Whether this effect will translate into survival benefit remains to be demon-
strated in larger study with longer follow up. Although cross-resistance of E with AT can be
reasonably excluded, and rather E was developed in patients with anthracycline- and taxane-
resistant tumors, the rate of pCR reported in our study is similar to that of anthracycline and
taxane-based regimens [13–14]. Nevertheless, E produced a profound down-regulation of
EMT biomarkers, as assessed in tumor specimens collected at surgery. Hence, we cannot
exclude the possibility of added benefit with E, as it is possible that it may slow progression
rather than provide complete tumor response. In fact, both in the EMBRACE study [26], and
in the previous phase II studies [31–32], which led to approval of E in the treatment of refrac-
tory metastatic BC patients, response rates were in the range of 9% and 12%, yet there was a
survival benefit. Furthermore, in a phase II randomized trial evaluating neoadjuvant chemo-
therapy regimens with weekly paclitaxel or E followed by doxorubicin and cyclophosphamide
in women with locally advanced HER2-negative breast cancer, pCR was lower in the E arm
than in the paclitaxel one (17 versus 26%) [33]. Therefore, additional research exploring E and
more in general EMT targeting drugs is warranted. Indeed, preclinical studies show that E is
able to trigger a shift from mesenchymal to epithelial phenotypes via reversal of the EMT to
the MET state [34–35]. This transition could be exploitable both to increase drug sensitivity,
and to combine with novel compounds, including immunotherapy [36]. Furthermore, a drug
capable of reversing EMT could be used to make tumors more sensitive to active drugs on the
epithelial component of the tumor. In this sense, E could be explored to be used in sequential
schemes to increase sensitivity, rather than to revert the resistance to anthracycline/taxane
combinations.
In conclusion, this study failed to demonstrate sufficient E efficacy as measured by pCR.
Despite E antitumor activity in anthracycline and taxane resistant BC, it could be possible that
E has greater impact upon acquired resistance in metastatic breast cancer. Alternatively, E
could have greater disease control rather than cytotoxic effect and pCR could not be the proper
endpoint to measure its activity. Interestingly, there are different ongoing studies testing the
benefit of E in non-metastatic breast cancer, and we are eagerly awaiting these results (https://
www.clinicaltrials.gov). However, since our trial was unable to meet its primary endpoint, we
still need to see what ultimate role, and in what clinical context, the modulation of the EMT
pathway mediated by E will play in the treatment of TNBC. One possibility is to look at
whether reducing EMT correlates with a reshaping of immune microenvironment, which can
be in turn exploitable for immune checkpoint Inhibitors combinations.
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